1Sinnis P,Sim B.K.L.Cell invasion by the vertebrate stages of Plasmodium.Trends in Microbiology,1997,5(2):52 58.
2Van Lin L.H.M.Janse C.J.Waters A.P ,The conserved genome organisation of non-falciparum malaria species:the need to know more,International Journal for Parasitology,2000,30:357-370.
3Mazier D,Nitcheu J,Idrissa-Boubou M.Cerebral malaria and immunogenetics.Parasite Immunol,2000,22(12):613 623.
5 Ancelin ML, Calas M, Bompart J, et al. Antimalarial activity of 77 phospholipidpolar head analogs: close correlation between inhibition of phospholipid metabolism and invitro Plasmodium falciparum growth[J].Blood,1998,91:1426．
6 Andersen SL, Oloo AJ, Gordon DM, et al.Successful double-blined, randomized,placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malariain western Kenya[J].Clin Infect Dis,1998,26:146.
7 Andersen SL, Ager A, McGreevy P, et al. Activity of azithromycin as a bloodschizonticide against rodent and human plasmodia in vivo[J]. Am J Trop Med Hyg,1995,52:159．
8 Posner GH, Oh CH, Webster HK, et al. New antimalarial tricyclic1,2,4-trioxanes: evaluations in mice and monkeys[J]. Am J Trop Med Hyg,1994,50:522．
9 Posner GH, Parker MH, Northrop J, et al.Orally active hydrolytically stablesemisynthetic antimalarial trioxanes in the artemisinin family[J]. J Med Chem,1999,42:300．
10 Posner GH, McGarvey DJ, Oh CH, et al. Structure-activity relationships oflactone ring-opened analogs of the antimalarial 1,2,4-trioxane artemisinin[J].J MedChem,1995,38:607．
10Moulin F, Lesage F, Legros AH,et al. Thrombocytopenia and Plasmodium falciparum malaria in children with different exposures[J]. Arch Dis Child,2003,88(6) :540-541
